Citation
Hage, J. A. van der. (2006, May 22). Impact of age, tumor characteristics, and treatment on
local control and disease outcome in early stage breat cancer : an EORTC translational
research project. Retrieved from https://hdl.handle.net/1887/4399
Version:
Corrected Publisher’s Version
Impact of age, tumor characteristics,
an d treatmen t on local con trol an d d isease outcome
in early stage b reast can cer.
A n EO R T C tran slation al research project
Impact of age, tumor characteristics, and treatment on local control and disease outcome in early stage breast cancer.
An EORTC translational research project
PROEFS CH RIFT
ter verkrijging van
de graad van D octor aan de U niversiteit Leiden, op gezag van de R ector M agnificu s D r.D .D .B reim er,
hoogleraar in de facu lteit der W isku nde en N atu u rw etenschap p en en die der G eneesku nde,
volgens beslu it van het College voor Prom oties te verdedigen op m aandag 22 m ei 2006
te klokke 16.15 u u r
door
Jos Alexander van der Hage
PROMOTIECOMMISSIE
Promotores: Prof. Dr. C.J.H. van de V elde Prof. Dr. G.J. Fleuren Co-promotor: Dr. M.J. van de V ijver Referent: Prof. Dr. J.W.R. Nortier Overige leden: Prof. Dr. R.A.E.M. Tollenaar
Prof. Dr. H. Bartelink Dr. E.J.Th. Rutgers Dr. P. Therasse
Part of this work was financially supported by the K oningin Wilhelmina Fonds (K WF). Publication of this thesis was financially supported by Abbott Nutrition International, AstraZ eneca BV, familie van der Hage, Integraal K ankercentrum West (IK W),
Johnson & Johnson Medical BV, K CI Medical BV, Novartis Pharma BV, Pfizer, Sanofi Aventis, Tyco Healthcare BV
Aan mijn ouders,
Chapter 1 . . . 11 G eneral introduction
PART I
Chapter 2 . . . 21 Improved survival after one course of perioperative chemotherapy in early breast cancer patients. Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854.
VAN D ERHAG EJA,VAN D EVELD ECJ, JU LIENJP, FLOIRASJL, DELOZ IERT, VAND ERVELD ENC, DU CHATEAU L.
EURJ CANCER. 2001 NOV;37(17):2184-93.
Chapter 3 . . . 33 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
VAN D ERHAG EJA,VAN D EVELD ECJ, JU LIENJP, TU BIANA-HU LINM, VAND ERVELD ENC, DU CHATEAU L.
J CLINONCOL. 2001 NOV15;19(22):4224-37.
Chapter 4 . . . 53 Clinical Tumor Response to Anthracycline Containing Preoperative Chemotherapy in W omen w ith Early Stage Breast Cancer: the Predictive Role of P53 Ex pression. MIEOG SJD ,VAN D ERHAG EJA,VAN D EVIJVERMJ,VANSLOOTENH-J, ELK HU IZ ENP, PU TTERH,
VAN D EVELD ECJH,AND COOPERATING INVESTIG ATORS OF THEEORTC.
ACCEPTED FOR PUBLICATION IN THEEUROPEANJOURNAL OFCANCER
PART II
Chapter 5 . . . 71 Overex pression of P70 S6 k inase protein is associated w ith increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients.
VAN D ERHAG EJA,VAN D ENBROEK LJ, LEG RAND C, CLAHSENPC, BOSCHCJ, ROBANU S-MAAND AG EC, VAN D EVELD ECJ,VAN D EVIJVERMJ.
Chapter 6 . . . 83 Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis.
VAN DERHAGEJA, PUTTERH, BONNEMAJ, BARTELINKH, THERASSEP,VAN DEVELDECJ;
EORTC BREASTCANCERGROUP.
EURJ CANCER. 2003 OCT;39(15):2192-9.
Chapter 7 . . . 97 Breast conserving therapy and young age are both independent prognostic factors associated with isolated loco-regional recurrences in early stage breast cancer.
DEBOCKGH,VAN DERHAGEJA, PUTTERH, BONNEMAJ, BARTELINKH,VAN DEVELDECJH.
EURJ CANCER. 2006 FEB42(3); 351-6.
PART III
Chapter 8 . . . 109 Impact of established prognostic factors in early stage breast cancer in very young breast cancer patients; a translational research project using pooled datasets derived from 4 EORTC Breast Group Trials.
VAN DERHAGEJA,VAN DEVELDECJH, PUTTERH, BARTELINKH,VAN DEVIJVERMJ,ON BEHALF OF THEEORTC BREASTCANCERGROUP.
Chapter 9 . . . 123 Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients.
VAN DERHAGEJA,VAN DEVIJVERMJ, PUTTERH, THERASSEP,VAN DEVELDECJH,AND COOPERATING INVESTIGATORS OF THEEUROPEANORGANIZATION FORRESEARCH ANDTREATMENT OFCANCER(EORTC).
